Welcome to BioSeeker Group!

Triple Analysis: Angiogenesis, Cancer Vaccines and Antibodies

Additional Information

Published Date Mar 19, 2013
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 5072
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Angiogenesis, Cancer Vaccines and Antibodies in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies by the two mechanism/target/effect areas of Angiogenesis and Cancer Vaccines and by the compound strategy of Antibodies.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Angiogenesis, Cancer Vaccines and Antibodies.

    To find out more about Triple Analysis: Angiogenesis, Cancer Vaccines and Antibodies, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Angiogenesis, Cancer Vaccines and Antibodies is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies by the two mechanism/target/effect areas of Angiogenesis and Cancer Vaccines and by the compound strategy of Antibodies. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Angiogenesis
The angiogenesis affecting cancer drug report part comprises defined and up to date development strategies for 252 drugs in oncology within the portfolio of 151 companies world-wide, from Ceased to Marketed. The report extensively analyses their 177 identified drug targets, organized into 170 drug target strategies, and assesses them in 70 cancer indications.
This part is based on the following publication:
Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

Part II: Cancer Vaccines
The cancer vaccine drug report part comprises defined and up to date development strategies for 196 drugs in oncology within the portfolio of 114 companies world-wide, from Ceased to Marketed. The report extensively analyses their 137 identified drug targets, organized into 114 drug target strategies, and assesses them in 52 cancer indications.
This part is based on the following publication:
Cancer Vaccines: From First-in-Class to Best-in-Class?

Part III: Antibodies
The antibody drug report part comprises defined and up to date development strategies for 572 drugs in oncology within the portfolio of 205 companies world-wide, from Ceased to Marketed. The report extensively analyses their 270 identified drug targets, organized into 279 drug target strategies, and assesses them in 72 cancer indications.
This part is based on the following publication:
Cancer Antibodies: Drug Target Atlas and Competitive Outlook

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Angiogenesis
5.1 The Scope of this Report 37
6 Consider the Therapeutic Target Among Angiogenesis Affecting Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (177 Drug Targets) 41-421
7 Emerging New Products to Established Ones: Drug Target Strategies of Angiogenesis Affecting Drugs in Oncology by their Highest Stage of Development (170 Drug Target Strategies and 252 Drugs) 424-666
8 Compound Strategies at Work: Competitive Benchmarking of Angiogenesis Affecting Cancer Drugs by Compound Strategy (7 Compound Strategies) 667-709
9 Selecting Indication for Angiogenesis Affecting Drugs in Oncology (70 Cancer Indications) 710-848
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Angiogenesis Affecting Drug Pipeline in Oncology by Investigator (151 Investigators and 252 Drugs) 849-1685
12 Drug Index 1687
13 Company Index 1697
Figures: Includes 7 Figures
Tables: Includes 310 Tables
Total Number of Pages: 1,704

Part II: Cancer Vaccines
5.1 The Scope of this Report 28
6 Consider the Therapeutic Target Among Cancer Vaccine Drugs for the Highest Therapeutic Outcome and Return on Investment (137 Drug Targets) 32-245
7 First-in-Class and Me-too Analysis of Cancer Vaccine Drugs (114 Drug Target Strategies and 196 Drugs) 246-262
8 Is First-in-Class the Best-in-Class? 263-386
9 Compound Strategies at Work: Competitive Benchmarking of Cancer Vaccine Drugs by Compound Strategy (7 Compound Strategies) 387-413
10 The Competition Through Close Mechanistic Approximation of Cancer Vaccine Drugs 414-416
11 Selecting Indications for Cancer Vaccine Drugs (52 Cancer Indications) 417-492
12 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Vaccine Drug Pipeline by Company (114 Companies and 196 Drugs) 493-993
13 Disclaimer 994
Figures: Includes 5 Figures
Tables: Includes 239 Tables
Total Number of Pages: 1,007

Part III: Antibodies
5.1 The Scope of this Report 35
6 Consider the Therapeutic Target Among Antibody Drugs in Cancer for the Highest Therapeutic Outcome and Return on Investment (270 Drug Targets) 39
7 Emerging Drug Candidates to Established Ones: Drug Target Strategies of Antibody Drugs in Cancer by their Highest Stage of Development (279 Drug Target Strategies and 572 Drugs) 423-776
8 Selecting Indication for Antibody Drugs in Oncology (72 Cancer Indications) 777-907
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Antibody Drug Pipeline by Investigator (205 Investigators and 572 Drugs) 908-2360
10 Disclaimer 2361
Figures: Includes 7 Figures
Tables: Includes 355 Tables
Total Number of Pages: 2,361

This Report Includes the Following Companies:
A&G Pharmaceutical
Abbott
Abcam
Abiogen
Ablynx
AC Immune
Acceleron Pharma
Access
Actinium Pharmaceuticals
Active Biotech
Adaptimmune
Adherex
Advantagene
Advaxis
Advenchen
AEterna Zentaris
Affibody
Affimed Therapeutics
Affitech
Agennix
Agenus
AGY Therapeutics
Aida Pharmaceuticals
Alder Biopharmaceuticals
Alethia Biotherapeutics
Alexion
Algeta
Alnylam
AlphaVax
ALSP
Altor BioScience
Ambit Biosciences
Ambrilia Biopharma
Amgen
Amorfix Life Sciences
Amphora
Angiogen
Angiogenex
Angstrom Pharmaceuticals
Ansaris
Antisoma
Anza Therapeutics
Aphios
Apricus Biosciences
Arana Therapeutics
Arca biopharma
Areva
arGEN-X
Argos Therapeutics
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Astellas
Astex Therapeutics
AstraZeneca
Attenuon
Austrianova
AVEO
Bavarian Nordic
Bayer
Bellicum Pharmaceuticals
Berkeley Lab
BioAlliance Pharma
BioAxone
Biocad
Biocon
Biogen Idec
BioInvent
Biolex
BioLineRx
BioNTech
BioSante
Biosceptre
Biostar
Biotecnol
Biotest
BioVex
Boehringer Ingelheim
Bolder BioTechnology
BreakThrough Therapeutics
Bristol-Myers Squibb
BTG
Cancer Advances
Cancer Innovations
Cancer Research Technology
CDG Therapeutics
Celecure
Celera
Celgene
Cell Therapeutics
CellCeutix
Celldex Therapeutics
Cellmid
Celltrion
Celtic Pharma
Center of Molecular Immunology
Centrose
Cephalon
CG Therapeutics
ChemoCentryx
Chemokine Therapeutics
China Sky One Medical
Choongwae
Circadian Technologies
Cosmo Pharmaceuticals
CreaGene
CSL
Cue Biotech
CuraGen
CureTech
CureVac
Curis
Customized Therapeutics
Cyclacel
CytImmune Sciences
Cytochroma
Daiichi Sankyo
Dainippon Sumitomo Pharma
Deciphera Pharmaceuticals
Dendreon
DeveloGen
DiaMedica
Dompe
Dr Reddy’s
Dyax
Eisai
Elan
Eli Lilly
Emergent BioSolutions
EntreMed
Epeius Biotechnologies
Ergon Pharmaceuticals
Etubics
EUSA Pharma
Exelixis
ExonHit Therapeutics
Expression Drug Designs
Fabrus
Faron Pharmaceuticals
Favrille
Femta Pharmaceuticals
FibroGen
Five Prime Therapeutics
Fusion Antibodies
Galaxy Biotech
Galena Biopharma
GammaCan
Ganymed Pharmaceuticals
Gene Techno Science
Genencor
Genentech
Generex
Genmab
GenOdyssee Pharmaceuticals
Genomic Systems
GenPat77
Genticel
Geron
Gilead Sciences
GlaxoSmithKline
Gliknik
GlobeImmune
GlycoGenesys
Glycotope
Gradalis
Green Cross
Hawthorn Pharmaceuticals
Heat Biologics
Hemispherx Biopharma
Hoffmann-La Roche
Human Genome Sciences
Hy BioPharma
Ichor Medical Systems
Idera Pharmaceuticals
IDM Pharma
ImClone Systems
IMED
immatics biotechnologies
Immune Pharmaceuticals
ImmunoCellular Therapeutics
ImmunoFrontier
ImmunoGen
Immunomedics
Immunotope
Immunovaccine
ImmuPharma
Immutep
Innate Pharma
InNexus Biotechnology
Inovio
Intracel
Introgen Therapeutics
ISA Pharmaceuticals
Isis Pharmaceuticals
ISU ABXIS
Jennerex Biotherapeutics
Johnson & Johnson
KAEL-GemVax
KAI Pharmaceuticals
Kaketsuken
KaloBios
Karus Therapeutics
Kirin Pharma
Kissei
Kringle Pharma
Kyowa Hakko Kirin
Kyto Biopharma
Lee’s Pharmaceutical
LFB Biotechnologies
LG Life Sciences
Lipotek
Lorus Therapeutics
MacroGenics
Mannkind
MAT Biopharma
Medarex
MediGene
MedImmune
Menarini
Merck & Co
Merck KGaA
Merrimack
Mersana Therapeutics
MethylGene
Micromet
Mitsubishi Tanabe Pharma
MolMed
Mologen
Momotaro-Gene
Morvus Technology
Mycenax
Nemod Biotherapeutics
Neovacs
Neuren
NewSouth Innovations
NIH
NKT Therapeutics
Non-industrial source
Northwest Biotherapeutics
Novartis
NovaRx
Novelix
Noxxon
Oasmia
OncoMed
OncoMune
Onconova
OncoTherapy Science
Oncothyreon
Oncovir
Onyvax
Orchestra Therapeutics
OSI Pharmaceuticals
Oxford BioMedica
OXiGENE
Paladin Labs
Panacea
PanGenetics
Patrys
Pepscan Therapeutics
Peptagen
PepTx
Peregrine Pharmaceuticals
Perseus Proteomics
Pfizer
PharmAbcine
Pharmacopeia
PharmaForm
PharmaMar
Pharmexa
Pharminox
Philogen
PhiloGene
Pierre Fabre
Prima Biomed
PROBIOMED
ProCell Therapeutics
Prochon Biotech
Progen
Progenics Pharmaceuticals
Protein Sciences
Protgen
Protherics
PTC Therapeutics
Radient Pharmaceuticals
Ramot
Recepta biopharma
Receptor BioLogix
Regeneron
responsif
Rexahn
Rigel
Sanofi
Santaris Pharma
Sarepta Therapeutics
SBI Biotech
Scancell
SciClone Pharmaceuticals
Seattle Genetics
Semafore Pharmaceuticals
Shanghai CP Guojian
Shenogen
Shionogi
Simcere Pharmaceuticals
Spear Therapeutics
SRI International
Stainwei Biotech
Sunol Molecular
SuperGen
SuppreMol
Switch Pharma
Symphogen
Synageva BioPharma
SynDevRx
SynerGene Therapeutics
Tactic Pharma
Taiho
Takeda
Tamir Biotechnology
TapImmune
Targa Therapeutics
Tau Therapeutics
TeGenero
Teva
Therion Biologics
ThromboGenics
Tigris Pharmaceuticals
Titan Pharmaceuticals
Tolerx
ToolGen
TopoTarget
Tracon Pharmaceuticals
Transgene
Trillium Therapeutics
Trion Pharma
UCB
United Biomedical
United Therapeutics
Vaccinex
Wakunaga
VasGene Therapeutics
Vaxil BioTherapeutics
Vaximm
Vaxon Biotech
VBL Therapeutics
Vectura
Vical
Wilex
Viragen
Virionics
ViroMed
Viventia Biotech
XBiotech
Xencor
Xerion
Xoma
Y’s Therapeutics
YM BioSciences
Zenotech
Zensun
Zydus Cadila
A Shortlist of Drugs Included are:
131I-tositumomab
A6
abagovomab
ABT-510
adecatumumab
ADXS11-001
AE-37
aflibercept
AGS-003
AGS-1C4D4
ALD-518
alemtuzumab
amatuximab
AME-133
AMG-386
Angiozyme
ANZ-207
apatinib
ARQ-197
astuprotimut-r
atrasentan
Auto TAG vaccine
AV-299
AVX-701
axitinib
belagenpumatucel-L
belimumab
bevacizumab
BHQ880
BIBF-1120
blinatumomab
BMS-663513
BMS-690514
BMS-936558
BP-GMAX-CD1
brentuximab vedotin
brivanib alaninate
BT-062
BV-NSCLC-001
carlumab
catumaxomab
CB-10-01
CDX-1307
CDX-1401
cediranib
cetuximab
CG-201
cilengitide
cixutumumab
CMAB302
CMAB304
conatumumab
CreaVax-PC
CT-011
CV-9103
CV-9201
CVac
dalotuzumab
daratumumab
DCVax-prostate
denosumab
DI-17E6
dovitinib lactate
E-75
E-7820
elotuzumab
EMD-273063
EMD525797
emepepimut-S
endostatin
ENMD-2076
enzastaurin hydrochloride
epratuzumab
epratuzumab-Y90
ertumaxomab
everolimus
Exherin
farletuzumab
figitumumab
foretinib
fosbretabulin tromethamine
fresolimumab
galiximab
ganitumab
gemtuzumab ozogamicin
GI-4000
girentuximab
glembatumumab vedotin
GliaAtak
GS-6634
GSK-2130579A
GT-111
GV-1001
GVAX
GVX-3322
HBP-347
Her-2/Neu peptides
Hi-8 MEL
HS-110
I-131-labetuzumab
ibritumomab tiuxetan
icrucumab
ICT-107
imMucin
IMO-2055
inotuzumab ozogamicin
interleukin-12
intetumumab
IPH-2102
ipilimumab
IPP-204106
iratumumab
ISA-P53-01
JI-101
JX-594
L19-TNFalpha
lenvatinib
linifanib
lintuzumab
LIP-131I
lorvotuzumab mertansine
lucatumumab
lumiliximab
LY-2275796
LY2495655
lymphomun
MABp1
mapatumumab
MCS-110
MDX-1379
MEDI-551
MEDI-573
MGCD-265
MGN-1601
midostaurin
milatuzumab
milatuzumab-doxorubicin
MM-111
MM-121
mogamulizumab
MOR202
MOR208
MORAb-004
motesanib diphosphate
moxetumomab pasudotox
muparfostat (IV)
MVA-BN Her-2 vaccine
naptumomab estafenatox
natalizumab
necitumumab
NGR-TNF
nimotuzumab
obinutuzumab
ofatumumab
olaratumab
ON-01910
onartuzumab
OncoVAX
Onyvax-105
oregovomab
OTS-102
p.DOM-WT1-37/p.DOM-WT1-126 DNA
paclitaxel
PancAtak
panitumumab
PAT-SC1
pazopanib hydrochloride
PCI-27483
pegdinetanib
pertuzumab
PF-4856884
plitidepsin
poly-ICLC
polyclonal antibody stimulator
ponatinib
ProstAtak
PROSTVAC
PSMA ADC
PTC-299
RAF-265
ramucirumab
Reditux
regorafenib
Reximmune-C
RG-7160
ridaforolimus
rilotumumab
rindopepimut
rintatolimod
rituximab
robatumumab
romiplostim
S-488410
samalizumab
SAR-3419
SCIB-1
siltuximab
sipuleucel-T
sirolimus
sorafenib tosylate
sotatercept
SU-6668
sunitinib malate
Survivac
Sym-004
talactoferrin alfa
TAS-102
tasquinimod
TB-403
telatinib
Tenarad
TG-4010
thymalfasin
tigatuzumab
tipapkinogene sovacivec
tipifarnib
tivozanib
tocilizumab
TRC-105
tremelimumab
TroVax
TRU-016
tucotuzumab celmoleukin
U3-1287
Ublituximab
vandetanib
velimogene aliplasmid
veltuzumab
verpasep caltespen
vismodegib
vitespen
volociximab
VX-001
XL-184
XL-647
yttrium Y 90 clivatuzumab tetraxetan
zalutumumab
zanolimumab

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Angiogenesis, Cancer Vaccines and Antibodies.
    To find out more about Triple Analysis: Angiogenesis, Cancer Vaccines and Antibodies, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Angiogenesis, Cancer Vaccines and Antibodies is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Melanoma, Pancreatic Cancer and Cancer Vaccines
This triple analysis focuses on cancer drug development strategies in both Melanoma and Pancreatic Cancer and by the mechanism/target/effect of Cancer Vaccines. Learn More


Triple Analysis: Colorectal Cancer, Leukemia and Prostate Cancer
This triple analysis focuses on cancer drug development strategies in Colorectal Cancer, Leukemia and Prostate Cancer. Learn More

Other selected research from the 'Oncology' category:


Commercial Interests at ASCO 2017 - A 1stOncology Insights Report - Academic License
The Academic License for the Commercial Interests at ASCO 2017 report is an invite only opportunity to get this must have companion tool for analyzing the direction of commercial drug development emerging from the American Society of Clinical Oncology (ASCO) Annual Meeting 2017 at an amazing 80% discount to the normal commercial pricing. Learn More


Vascular Targeting Agents: Emerging Competitors
An update on the most recent advances made for vascular targeting agents that are now entering an exciting stage of development. Learn More